Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?. Issue 5 (11th September 2018)

• Record Type: Journal Article
• Authors: Eichler, Hans‐Georg; Bedlington, Nicola; Boudes, Mathieu; Bouvy, Jacoline C.; Broekmans, André W.; Cerreta, Francesca; Faulkner, Stuart D.; Forda, Susan R.; Joos, Angelika; Le Cam, Yann; Mayer, Mark H.; Pirard, Vinciane; Corriol‐Rohou, Solange
• Is Part Of: Clinical pharmacology & therapeutics. Volume 105:Issue 5(2019)
• Page Start: 1148
• Page End: 1155
• Publication Date: 2018-09-11
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1121
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the "evidence vs. access" conundrum.